Skip to content
TrialScanner

NCT03232567

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Phase 2CompletedALTLead

Registry record

Lead sponsor
Altimmune, Inc.
Conditions
Influenza
Primary completion
Mar 7, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03232567 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.